Tomosynthesis Mammographic Imaging Screening Trial (TMIST) principal investigator Etta Pisano, MD, will show attendees of two sessions how they can make the most of TMIST Trial participation at the upcoming 2019 Society of Breast Imaging (SBI)/American College of Radiology (ACR) Breast Imaging Symposium.
60 sites are now open and accruing patients. The trial will add 80 more sites and enroll 165,000 healthy women, ages 45 to 74, who are already planning to get routine mammograms.
TMIST is the first large randomized, controlled trial (RCT) that would identify women in which digital breast tomosynthesis (DBT) may outpace digital mammography at reducing advanced breast cancer development.
SBI attendees are invited to attend these sessions.
Thursday, April 4 at 5pm ET in Conference Room 303
Pisano will explain to those interested in having their facilities become new TMIST sites how TMIST participation can:
- Strengthen a practice’s bottom line with $500 reimbursement for each patient enrolled and $150 for each follow-up exam — in addition to the patient’s insurance payment
- Empower a site to expand screening to the underserved in the community with $288 per screening exam ($138.17 for performing exam + $150 for data submission for exam) for uninsured participants who qualify for charity care at a site
- Enable participants to shape future breast cancer screening
- The study provides additional payment to sites for submission of biopsy, blood and buccal smear samples that patients are asked to provide.
- These submissions will create the world’s largest breast cancer screening biorepository to help tailor future, risk-based screening policy
Friday, April 5 at 6:30am ET in Conference Room 307
Pisano will update participating TMIST investigators on the current state of the trial — as well as how:
- Site investigators can become coauthors of TMIST papers published in large medical journals
- TMIST offers networking opportunities to learn from fellow investigators’ experiences and brainstorm over participation in other ECOG-ACRIN trials
- The 165,000 patients in TMIST dwarfs most treatment or industry-sponsored studies and allows for significant reimbursement that more than pays for resources needed for trial participation
- A recently approved $30,000 reimbursement advance can help select facilities immediately hire a research assistant as an on-site coordinator and forego added responsibilities to existing staff
TMIST is necessary to inform tomosynthesis clinical and payment updates. Decision makers rarely update clinical or payment policy without such a large RCT in the evidence base.
If you cannot attend these sessions at SBI, please take advantage of the TMIST resources below.
Visit acr.org/TMIST to get more information on how your practice can become a TMIST site.
Email TMIST@acr.org with any questions you may have about TMIST.
|Dr. Etta Pisano explains the benefits of TMIST participation|